Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTXNASDAQ:ONCNASDAQ:RVMDNASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$94.74-6.3%$99.87$76.53▼$131.49$22.73B1.35912,716 shs1.84 million shsONCBeigene$241.75-4.9%$247.33$141.31▼$287.88$23.91B0.35480,243 shs874,927 shsRVMDRevolution Medicines$37.44-5.9%$37.29$29.17▼$62.40$6.97B1.111.45 million shs3.09 million shsSMMTSummit Therapeutics$24.20-13.6%$21.67$2.10▼$36.91$17.97B-0.943.85 million shs4.37 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech-6.29%-8.90%+7.60%-22.59%+1.49%ONCBeigene-4.88%-3.21%+1.36%+24,174,999,900.00%+24,174,999,900.00%RVMDRevolution Medicines-5.91%-7.94%+19.54%-15.39%-4.12%SMMTSummit Therapeutics-13.63%+2.46%+39.40%+16.46%+441.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNTXBioNTech2.4431 of 5 stars4.42.00.00.02.50.80.0ONCBeigene2.8145 of 5 stars4.50.00.00.01.61.70.6RVMDRevolution Medicines3.8028 of 5 stars3.50.00.04.74.02.50.0SMMTSummit Therapeutics2.8116 of 5 stars4.51.00.00.03.81.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTXBioNTech 2.89Moderate Buy$142.7350.66% UpsideONCBeigene 3.00Buy$318.8831.90% UpsideRVMDRevolution Medicines 3.00Buy$66.6778.06% UpsideSMMTSummit Therapeutics 3.00Buy$37.4054.55% UpsideCurrent Analyst Ratings BreakdownLatest RVMD, ONC, BNTX, and SMMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2025BNTXBioNTechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$145.00 ➝ $140.005/6/2025BNTXBioNTechMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$140.00 ➝ $132.005/2/2025SMMTSummit TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$37.00 ➝ $41.004/28/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$44.004/28/2025ONCBeigeneRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$312.00 ➝ $312.004/28/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$67.00 ➝ $67.004/28/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$40.00 ➝ $40.004/25/2025SMMTSummit TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$31.00 ➝ $44.004/24/2025ONCBeigeneTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$334.00 ➝ $334.004/23/2025SMMTSummit TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight4/21/2025ONCBeigeneJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$311.00 ➝ $317.00(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTXBioNTech$2.75B8.26$4.07 per share23.25$92.17 per share1.03ONCBeigene$3.81B6.28N/AN/A$37.10 per share6.52RVMDRevolution Medicines$742K9,398.45N/AN/A$11.09 per share3.38SMMTSummit Therapeutics$700K25,675.02N/AN/A$0.11 per share220.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTXBioNTech$1.01B-$3.00N/AN/AN/A-15.16%-2.35%-2.05%N/AONCBeigene-$881.71M-$6.14N/A340.497.73-25.94%-25.12%-14.95%N/ARVMDRevolution Medicines-$436.37M-$3.57N/AN/AN/AN/A-33.67%-30.08%5/7/2025 (Estimated)SMMTSummit Therapeutics-$614.93M-$0.34N/AN/AN/AN/A-85.42%-52.66%N/ALatest RVMD, ONC, BNTX, and SMMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025RVMDRevolution Medicines-$1.10N/AN/AN/AN/AN/A5/1/2025Q1 2025SMMTSummit Therapeutics-$0.10-$0.09+$0.01-$0.09N/AN/A3/10/2025Q4 2024BNTXBioNTech$0.38$1.08+$0.70$1.15$1.24 billion$1.19 billion2/27/2025Q4 2024ONCBeigene-$0.88-$1.43-$0.55-$1.43$1.09 billion$1.13 billion2/26/2025Q4 2024RVMDRevolution Medicines-$1.01-$1.12-$0.11-$1.12$0.35 millionN/A2/24/2025Q4 2024SMMTSummit Therapeutics-$0.08-$0.08N/A-$0.08N/A$0.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNTXBioNTech$1.531.61%N/AN/A N/AONCBeigeneN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTXBioNTech0.017.337.21ONCBeigene0.051.931.72RVMDRevolution MedicinesN/A14.2414.24SMMTSummit TherapeuticsN/A8.318.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTXBioNTech15.52%ONCBeigene48.55%RVMDRevolution Medicines94.34%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipBNTXBioNTech19.20%ONCBeigene6.62%RVMDRevolution Medicines8.00%SMMTSummit Therapeutics88.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTXBioNTech3,080239.97 million193.71 millionOptionableONCBeigene9,00098.91 million90.59 millionN/ARVMDRevolution Medicines250186.26 million154.76 millionOptionableSMMTSummit Therapeutics110742.67 million86.28 millionOptionableRVMD, ONC, BNTX, and SMMT HeadlinesRecent News About These CompaniesBayesian Capital Management LP Invests $1.20 Million in Summit Therapeutics Inc. (NASDAQ:SMMT)May 7 at 5:49 AM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Rating Lowered to "Sell" at StockNews.comMay 7 at 2:21 AM | americanbankingnews.comWall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should KnowMay 6 at 11:00 AM | zacks.comBellevue Group AG Has $3.04 Million Stock Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT)May 6 at 6:33 AM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Issues Quarterly Earnings ResultsMay 5 at 3:34 PM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Issues Earnings ResultsMay 5 at 2:06 PM | marketbeat.comTower Research Capital LLC TRC Raises Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT)May 5 at 4:04 AM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Price Target Raised to $41.00May 5 at 3:01 AM | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Trading 16.9% Higher After Better-Than-Expected EarningsMay 4 at 10:50 AM | marketbeat.comWhy Summit Therapeutics Inc. (SMMT) Soared Last WeekMay 4 at 7:21 AM | insidermonkey.com250,000 Shares in Summit Therapeutics Inc. (NASDAQ:SMMT) Acquired by Boxer Capital Management LLCMay 4 at 6:25 AM | marketbeat.comSusquehanna Fundamental Investments LLC Makes New $1.20 Million Investment in Summit Therapeutics Inc. (NASDAQ:SMMT)May 4 at 4:35 AM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Up 16.9% Following Better-Than-Expected EarningsMay 4 at 1:43 AM | americanbankingnews.comQ2 EPS Forecast for Summit Therapeutics Reduced by AnalystMay 3, 2025 | marketbeat.comHC Wainwright Analysts Lower Earnings Estimates for SMMTMay 3, 2025 | americanbankingnews.comThis Soaring Stock Just Delivered More Good News. Time to Buy?May 2, 2025 | finance.yahoo.comSummit Therapeutics Q1 Loss Narrower Than Expected, Sales NilMay 2, 2025 | zacks.comSummit Therapeutics Inc. (NASDAQ:SMMT) Q1 2025 Earnings Call TranscriptMay 2, 2025 | insidermonkey.comSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025May 1, 2025 | businesswire.comSummit Therapeutics (NasdaqGM:SMMT) Sees 16% Stock Price Increase Over Past MonthApril 30, 2025 | finance.yahoo.comSummit Therapeutics (NASDAQ:SMMT) Sees Unusually-High Trading Volume - What's Next?April 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesPalantir Earnings: 1 Bullish Signal and 1 Area of ConcernBy Chris Markoch | May 2, 2025View Palantir Earnings: 1 Bullish Signal and 1 Area of ConcernInvestors Sell Microsoft Stock on OpenAI News—Time to Buy? By Chris Markoch | April 22, 2025View Investors Sell Microsoft Stock on OpenAI News—Time to Buy? Viking Therapeutics Stock Pops But Struggles to Hold GainsBy Chris Markoch | April 16, 2025View Viking Therapeutics Stock Pops But Struggles to Hold Gains3 Stocks To Watch For When Tariffs Subside By Gabriel Osorio-Mazilli | April 25, 2025View 3 Stocks To Watch For When Tariffs Subside Marvell Gets Tariff Lifeline But Expect More VolatilityBy Chris Markoch | April 11, 2025View Marvell Gets Tariff Lifeline But Expect More VolatilityRVMD, ONC, BNTX, and SMMT Company DescriptionsBioNTech NASDAQ:BNTX$94.74 -6.36 (-6.29%) Closing price 05/6/2025 04:00 PM EasternExtended Trading$97.38 +2.64 (+2.78%) As of 06:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Beigene NASDAQ:ONC$241.75 -12.41 (-4.88%) As of 05/6/2025 04:00 PM EasternBeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.Revolution Medicines NASDAQ:RVMD$37.44 -2.35 (-5.91%) Closing price 05/6/2025 04:00 PM EasternExtended Trading$37.42 -0.02 (-0.05%) As of 04:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Summit Therapeutics NASDAQ:SMMT$24.20 -3.82 (-13.63%) Closing price 05/6/2025 04:00 PM EasternExtended Trading$24.76 +0.56 (+2.29%) As of 06:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Top-Ranked Insider Buys From April by Market Cap Palantir Stock Drops Despite Stellar Earnings: What's Next? Hims & Hers Stock Rises on Fundamentals and Squeeze Potential Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership? D-Wave Quantum: Hidden Opportunity or Short Seller's Dream? Microsoft Stock After Xbox Price Hike: Buy or Hold? Uncertainty Creates Opportunity for Tyson Foods Investors Why Wells Fargo Is Buying $40 Billion of Its Own Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
